Literature DB >> 18202526

The prevalence of benign and malignant tumors in patients with acromegaly at a single institute.

Makiko Kurimoto1, Izumi Fukuda, Naomi Hizuka, Kazue Takano.   

Abstract

It has been reported that patients with acromegaly may have an increased risk of developing several types of cancers, such as colorectal, breast and prostate tumors. However, some reports do not support these findings and therefore the prevalence of cancers in patients with acromegaly remains controversial. In this study, we determined the prevalence of benign and malignant neoplasms in patients with acromegaly. A retrospective chart analysis was performed on 140 patients with active acromegaly who had attended our outpatient clinic (M/F 54/86, age 55 +/- 25 yr, range 21-86). Colon cancer was found in 10 patients, thyroid cancer in 5, breast cancer in 4 and gastric cancer in 2. When compared with the local population, the standardized incidence ratios (SIRs) for thyroid cancer in patients with acromegaly were 61.74 (95% confidence interval (CI): 0.51-114.63) for females and 272.4 (95% CI: 29.12-876.71) for males. The SIRs for colon cancer in the acromegalic patients were 17.4 (95% CI: 4.74-44.55) for females and 19.0 (95% CI: 5.18-48.64) for male patients in comparison with the local population. Of the benign tumors, multinodular goiter and colonic, gastric and gallbladder polyps were observed in 57% (47/83), 40% (35/87), 23% (10/43), and 14% (11/77) [corrected] of the patients, respectively. This study suggested that patients with acromegaly have an increased risk of colon cancer and polyps. Moreover, it is speculated that the risk for thyroid cancer is increased in male patients. It is therefore recommended that patients with acromegaly should undergo screening colonoscopy and ultrasonography of the thyroid.

Entities:  

Mesh:

Year:  2008        PMID: 18202526     DOI: 10.1507/endocrj.k07e-010

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  20 in total

Review 1.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

2.  Thyroid cancer is the most common cancer associated with acromegaly.

Authors:  Bennur Esen Gullu; Ozlem Celik; Nurperi Gazioglu; Pinar Kadioglu
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

3.  Increased thyroid cancer risk in acromegaly.

Authors:  Selcuk Dagdelen; Nese Cinar; Tomris Erbas
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

4.  Thyroid cancer in patients with acromegaly: a case-control study.

Authors:  Maíra Cristina Carvalho dos Santos; Gilvan Cortês Nascimento; Ana Gisélia Cortês Nascimento; Viviane Chaves Carvalho; Maria Honorina Cordeiro Lopes; Renan Montenegro; Renan Montenegro; Lucio Vilar; Mônica Fiterman Albano; Alice Regina Vasconcelos Alves; Conceição Veiga Parente; Manuel dos Santos Faria
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

5.  Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly.

Authors:  A Taslipinar; E Bolu; L Kebapcilar; M Sahin; G Uckaya; M Kutlu
Journal:  Med Oncol       Date:  2008-07-29       Impact factor: 3.064

6.  Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients.

Authors:  Serkan Dogan; Aysegul Atmaca; Selcuk Dagdelen; Belkis Erbas; Tomris Erbas
Journal:  Endocrine       Date:  2013-05-14       Impact factor: 3.633

7.  Increased risk of preneoplastic colonic lesions and colorectal carcinoma in acromegaly: multicenter case-control study.

Authors:  Maria Florencia Battistone; Karina Miragaya; Amelia Rogozinski; Monica Agüero; Analia Alfieri; Maria Carolina Ballarino; Laura Boero; Karina Danilowicz; Sabrina Diez; Marina Donoso; Patricia Fainstein-Day; Alejandra Furioso; Natalia Garcia-Basavilbaso; Mariela Glerean; Debora Katz; Monica Loto; Susana Mallea-Gil; Marcela Martinez; Maria Isabel Sabate; Marisa Servidio; Patricia Slavinsky; Graciela Stalldecker; Soledad Sosa; Grabriela Szuman; Julieta Tkatch; Ignacio Caldo; Daniela Lubieniecki; Mirtha Guitelman
Journal:  Pituitary       Date:  2020-10-15       Impact factor: 4.107

8.  The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study.

Authors:  Masaaki Yamamoto; Hidenori Fukuoka; Genzo Iguchi; Ryusaku Matsumoto; Michiko Takahashi; Hitoshi Nishizawa; Kentaro Suda; Hironori Bando; Yutaka Takahashi
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

9.  Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer.

Authors:  A Raitila; M Georgitsi; E Bonora; M Vargiolu; K Tuppurainen; M J Mäkinen; O Vierimaa; P I Salmela; V Launonen; P Vahteristo; L A Aaltonen; G Romeo; A Karhu
Journal:  J Endocrinol Invest       Date:  2009-05       Impact factor: 4.256

10.  Prevalence of comorbidities and associated factors in acromegaly patients in the Turkish population

Authors:  Mustafa Can; Muhammet Kocabaş; İlker Çordan; Hatice Çalışkan Burgucu; Melia Karaköse; Mustafa Kulaksızoğlu; Feridun Karakurt
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.